vTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025.
Latest vTv Therapeutics news
We have not published a story on vTv Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $86.6 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about vTv Therapeutics
Has vTv Therapeutics raised money recently?
Our latest story on this, dated Sep 2, 2025: "vTv Therapeutics agrees to private placement of about $80 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of vTv Therapeutics?
vTv Therapeutics Inc. trades under the ticker VTVT on NASDAQ.
Where is vTv Therapeutics listed?
vTv Therapeutics Inc. is listed on NASDAQ.
What is the SEC CIK of vTv Therapeutics?
The SEC Central Index Key (CIK) for vTv Therapeutics Inc. is 1641489. Its filings are on SEC EDGAR.
Which country or territory is vTv Therapeutics listed under?
Our directory records vTv Therapeutics Inc. under United States.
What does vTv Therapeutics do?
Our directory classifies vTv Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of vTv Therapeutics?
The ISIN recorded for vTv Therapeutics Inc. is US9183852048.
Does aibio.space cover vTv Therapeutics?
aibio.space lists vTv Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is vTv Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was vTv Therapeutics's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is vTv Therapeutics profitable?
vTv Therapeutics Inc. reported a net loss of $27.0 million for the fiscal year ended Dec 31, 2025, and used $25.3 million of cash in operations, per its annual report to the SEC.
How much does vTv Therapeutics spend on research and development?
$17.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does vTv Therapeutics have?
$86.6 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest vTv Therapeutics (VTVT) stock news?
Our latest story on vTv Therapeutics, dated Sep 2, 2025: "vTv Therapeutics agrees to private placement of about $80 million". vTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025. Source.
What is vTv Therapeutics's market cap?
We do not publish live share prices. In its annual report, vTv Therapeutics Inc. put the market value of shares held by non-affiliates (public float) at $22.4 million as of Jun 30, 2025.
Investor discussion: vTv Therapeutics
Members talk about vTv Therapeutics (VTVT). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at vTv Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:VTVT on TradingView.
SEC filings and registration
SEC name
vTv Therapeutics Inc.
CIK
1641489
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
VTVT (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
3980 PREMIER DR, HIGH POINT, NC, 27265
Phone
336-841-0300
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
vTv Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VTVT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio